T. Rowe Price Associates
TXG icon

T. Rowe Price Associates’s 10x Genomics TXG Stock Holding History

T. Rowe Price Associates’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.47M Buy
163,215
+44,844
+38% +$896K ﹤0.01% 1586
2025
Q4 		$1.93M Sell
118,371
-34,459
-23% -$521K ﹤0.01% 1764
2025
Q3 		$1.79M Sell
152,830
-118,248
-44% -$1.54M ﹤0.01% 1782
2025
Q2 		$3.14M Buy
271,078
+19,814
+8% +$181K ﹤0.01% 1456
2025
Q1 		$2.19M Sell
251,264
-1,530,004
-86% -$19.3M ﹤0.01% 1566
2024
Q4 		$25.6M Sell
1,781,268
-734,635
-29% -$11.6M ﹤0.01% 931
2024
Q3 		$56.8M Sell
2,515,903
-358,049
-12% -$7.4M 0.01% 717
2024
Q2 		$55.9M Sell
2,873,952
-783,275
-21% -$20.5M 0.01% 685
2024
Q1 		$137M Buy
3,657,227
+553,053
+18% +$24.3M 0.02% 491
2023
Q4 		$174M Buy
3,104,174
+416,723
+16% +$18.1M 0.02% 438
2023
Q3 		$111M Buy
2,687,451
+30,127
+1% +$1.57M 0.02% 496
2023
Q2 		$148M Buy
2,657,324
+243,364
+10% +$13.2M 0.02% 445
2023
Q1 		$135M Buy
2,413,960
+401,785
+20% +$18.8M 0.02% 465
2022
Q4 		$73.3M Sell
2,012,175
-337,054
-14% -$11M 0.01% 561
2022
Q3 		$66.9M Buy
2,349,229
+1,010,643
+76% +$38.5M 0.01% 573
2022
Q2 		$60.6M Buy
1,338,586
+187,833
+16% +$9.75M 0.01% 823
2022
Q1 		$87.5M Buy
1,150,753
+73,541
+7% +$6.43M 0.01% 773
2021
Q4 		$160M Buy
1,077,212
+105,195
+11% +$16.1M 0.01% 616
2021
Q3 		$142M Sell
972,017
-92,621
-9% -$15.9M 0.01% 659
2021
Q2 		$208M Buy
1,064,638
+233,535
+28% +$42.3M 0.02% 544
2021
Q1 		$150M Sell
831,103
-25,183
-3% -$4.35M 0.02% 642
2020
Q4 		$121M Buy
856,286
+177,172
+26% +$25.7M 0.01% 671
2020
Q3 		$84.7M Buy
679,114
+289,604
+74% +$30.4M 0.01% 709
2020
Q2 		$34.8M Buy
389,510
+44,616
+13% +$3.48M ﹤0.01% 975
2020
Q1 		$21.5M Buy
344,894
+160,810
+87% +$12.6M ﹤0.01% 1047
2019
Q4 		$14M Sell
184,084
-497,316
-73% -$29.9M ﹤0.01% 1255
2019
Q3 		$34.3M Buy
+681,400
New +$37.7M ﹤0.01% 990

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's TXG Position: Q1 2026 in Review

T. Rowe Price Associates increased its 10x Genomics (TXG) stake by 38% in Q1 2026, buying an estimated $896K and bringing the position to 163,215 shares worth $3.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

T. Rowe Price Associates first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $208M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • T. Rowe Price Associates held 163,215 shares of 10x Genomics worth $3.47M as of Q1 2026.
  • T. Rowe Price Associates bought 44,844 10x Genomics shares in Q1 2026, an estimated $896K.
  • 10x Genomics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1586 holding.
  • T. Rowe Price Associates first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • T. Rowe Price Associates's 10x Genomics position peaked at $208M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.